Eiger Biopharmaceuticals Inc (EIGR) Has Another Very Strong Trading Session

September 17, 2017 - By Winifred Garcia

The stock of Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) is a huge mover today! The stock increased 6.19% or $0.65 on September 15, reaching $11.15. About 60,942 shares traded or 6.85% up from the average. Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) has declined 64.64% since September 17, 2016 and is downtrending. It has underperformed by 81.34% the S&P500.
The move comes after 8 months positive chart setup for the $93.29M company. It was reported on Sep, 17 by Barchart.com. We have $11.60 PT which if reached, will make NASDAQ:EIGR worth $3.73 million more.

Investors wait Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) to report on November, 14. its quarterly earnings Wall Street analysts expect $-1.26 earnings per share, up $0.23 or 15.44 % from last year’s $-1.49 same quarter earnings. Eiger Biopharmaceuticals Inc’s Wall Street analysts see -5.26 % EPS growth, taking into account the $-1.33 EPS reproted in the previous quarter,

More notable recent Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) news were published by: Marketwatch.com which released: “11.15” on March 24, 2016, also Prnewswire.com with their article: “Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 ULTRA Study …” published on July 25, 2016, Prnewswire.com published: “Eiger BioPharmaceuticals Announces License of Worldwide Rights to Pegylated …” on April 20, 2016. More interesting news about Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) were released by: 247Wallst.com and their article: “Does Eiger BioPharmaceuticals Really Have 400% Upside?” published on June 21, 2017 as well as Prnewswire.com‘s news article titled: “Eiger Announces First Patient Dosed in Phase 2 Study of Pegylated Interferon …” with publication date: October 19, 2016.

Eiger BioPharmaceuticals, Inc., formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The company has market cap of $93.29 million. The Firm is focused on the development and commercialization of products for the treatment of orphan diseases. It currently has negative earnings. The Company’s pipeline includes Sarasar for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.